Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyIndolent LymphomasDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentSubgroupRichter transformation, DLBCLICD10C82.-C82.7C82.9C83.1C83.3C83.7C91.0-C91.1-MeSHLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MOLTO: OBIN(100/900/1000)/ATEZ1200/VNTC20, CLL (Richter Syndrome), C1 (PID2778) -|- C2 (PID2779) -|- C3-8 (PID2780) -|- C9-18 (PID2781) -|- C19-35 (PID2782)OXAL25/FLUD30/CYTA1000/RITU375, CLL-RT, C1 (PID828) -|- C2+ (PID829)ChemotherapyChemo-substanceAtezolizumabCyclophosphamideCytarabineFludarabineObinutuzumabOxaliplatinRituximabTislelizumabVenetoclaxZanubrutinibChemo-substanceAtezolizumabCyclophosphamideCytarabineFludarabineObinutuzumabOxaliplatinRituximabTislelizumabVenetoclaxZanubrutinibChemo-substanceAtezolizumabCyclophosphamideCytarabineFludarabineObinutuzumabOxaliplatinRituximabTislelizumabVenetoclaxZanubrutinibChemo-substanceAtezolizumabCyclophosphamideCytarabineFludarabineObinutuzumabOxaliplatinRituximabTislelizumabVenetoclaxZanubrutinibNo. Substances1234 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances13479Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlArthalgiaBleedingCOVID-19 infectionDiarrheaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHemorrhageHypercalcemiaHypertensionHypokalemiaIncrease AminotransferasesInfusion ReactionLymphopeniaNeutropeniaPneumoniaPruritusRashSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorAl-Sawaf ODavies ALiu E Tedeschi ATsimberidou ADiseaseB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieCLL (Richter Transformation)Fludarabin-refraktäre CLL oder Transormation zum Richter Syndrom, ECOG 0-2Richter Transformation (DLBCL) bei chronischer lymphatischer LeukämieOriginASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy, MOLTO trialCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCenter for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Germany, RT1 trialDepartments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center Departments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center HoustonUniversity of Texas M.D. Anderson Cancer Center, HoustonProtocols in Revision 10 protocols foundProtocols under revision.Atezolizumab 1200 / Venetoclax 400, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 9-18 (PID2781 V1.0)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)Obinutuzumab (100/900/1000) / Atezolizumab 1200 / Venetoclax 20, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 1 (PID2778 V1.0)Obinutuzumab 1000 / Atezolizumab 1200 / Venetoclax (50/100/200), Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 2 (PID2779 V1.0)Obinutuzumab 1000 / Atezolizumab 1200 / Venetoclax 400, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 3-8 (PID2780 V1.0)Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 2+ (PID829 V1.1)Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 1 (PID828 V1.1)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Tislelizumab 200 / Zanubrutinib 160, Chronic Lymphocytic Leukemia, Richter Transformation (PID2840 V1.0)Venetoclax 400, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 19-35 (PID2782 V1.0)
